Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells

Joong Sup Shim; Jiyong Lee; Kyung Noo Kim; Ho Jeong Kwon

doi:10.1016/j.bbrc.2007.05.174

Development of a new Ca²⁺/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells

Joong Sup Shim, Jiyong Lee, Kyung Noo Kim, Ho Jeong Kwon

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

We previously identified a cellular target of a cell cycle inhibitor HBC as Ca²⁺/calmodulin (Ca²⁺/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca²⁺/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca²⁺/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21^WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G₀/G₁ cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca²⁺/CaM antagonist and can be applied for CaM related therapeutic uses.

Original language	English
Pages (from-to)	747-751
Number of pages	5
Journal	Biochemical and Biophysical Research Communications
Volume	359
Issue number	3
DOIs	https://doi.org/10.1016/j.bbrc.2007.05.174
Publication status	Published - 2007 Aug 3

Bibliographical note

Funding Information:
We are grateful to Drs. J.M. Kim and W.J. Lee of Digital Genomics for their valuable comments. This study was partially supported by grants from the Chemical Genomics program and the National Research Laboratory from the Korean Ministry of Science and Technology and from the Brain Korea 21 Project, Republic of Korea.

All Science Journal Classification (ASJC) codes

Biophysics
Biochemistry
Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bbrc.2007.05.174

Cite this

@article{5240d553b7854ca9968f4d2be28797b1,

title = "Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells",

abstract = "We previously identified a cellular target of a cell cycle inhibitor HBC as Ca2+/calmodulin (Ca2+/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca2+/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca2+/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G0/G1 cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca2+/CaM antagonist and can be applied for CaM related therapeutic uses.",

author = "Shim, {Joong Sup} and Jiyong Lee and Kim, {Kyung Noo} and Kwon, {Ho Jeong}",

note = "Funding Information: We are grateful to Drs. J.M. Kim and W.J. Lee of Digital Genomics for their valuable comments. This study was partially supported by grants from the Chemical Genomics program and the National Research Laboratory from the Korean Ministry of Science and Technology and from the Brain Korea 21 Project, Republic of Korea. ",

year = "2007",

month = aug,

day = "3",

doi = "10.1016/j.bbrc.2007.05.174",

language = "English",

volume = "359",

pages = "747--751",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells

AU - Shim, Joong Sup

AU - Lee, Jiyong

AU - Kim, Kyung Noo

AU - Kwon, Ho Jeong

N1 - Funding Information: We are grateful to Drs. J.M. Kim and W.J. Lee of Digital Genomics for their valuable comments. This study was partially supported by grants from the Chemical Genomics program and the National Research Laboratory from the Korean Ministry of Science and Technology and from the Brain Korea 21 Project, Republic of Korea.

PY - 2007/8/3

Y1 - 2007/8/3

N2 - We previously identified a cellular target of a cell cycle inhibitor HBC as Ca2+/calmodulin (Ca2+/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca2+/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca2+/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G0/G1 cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca2+/CaM antagonist and can be applied for CaM related therapeutic uses.

AB - We previously identified a cellular target of a cell cycle inhibitor HBC as Ca2+/calmodulin (Ca2+/CaM) through chemical genetics approach. Using the mechanism-based drug design, we developed a new Ca2+/CaM antagonists based on the structure of HBC. The compound, (4-{3,5-bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-4,5-dihydro-pyrazol-1-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone (referred as HBCP), binds to Ca2+/CaM in vitro and inhibits the proliferation of HCT15 colon cancer cells. HBCP induced sustained phosphorylation of ERK1/2 and subsequently activated p21WAF1 expression in HCT15 cells. Moreover, HBCP reversibly induced the G0/G1 cell cycle arrest in the cells. These data demonstrate that HBCP is a new potent Ca2+/CaM antagonist and can be applied for CaM related therapeutic uses.

UR - http://www.scopus.com/inward/record.url?scp=34250208088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250208088&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2007.05.174

DO - 10.1016/j.bbrc.2007.05.174

M3 - Article

C2 - 17559805

AN - SCOPUS:34250208088

SN - 0006-291X

VL - 359

SP - 747

EP - 751

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 3

ER -